West Pharmaceutical Services, Inc.

WSTNYSEHealthcare● Active

$316.40

+$1.90(+0.60%)

Market Cap$22.4B

P/E Ratio—

52W High$330.88

52W Low$206.8

Avg Volume882K

Open$317.43

Beta1.18

Free Cash Flow Financials Revenue

West Pharmaceutical Services, Inc. (WST) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

WST · free cash flow · updated Jun 8, 2026

Core FCF metrics

WST · FCF · TTM · margin & CAGR

Free cash flow was $468.9M for FY2025 (fiscal year ending 2025-12-31), up 69.6% year-over-year The FCF margin was 15.3%. Five-year CAGR stands at +9.5%.

FY2025 Free Cash Flow$468.9M▲ +69.6% YoY

Trailing 12M (TTM)$458.0Mtrailing 4 quarters sum

FCF Margin15.3%$468.9M ÷ revenue

3-Year CAGR+2.2%FY2022 → FY2025

5-Year CAGR+9.5%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

WST · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$754.8M(286M)$468.9M▲ +69.6%15.3%

FY2024$653.4M(377M)$276.4M▼ 33.3%9.6%

FY2023$776.5M(362M)$414.5M▼ 5.7%14.1%

FY2022$724.0M(285M)$439.4M▲ +32.9%15.2%

FY2021$584.0M(253M)$330.6M▲ +10.9%11.7%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

WST · P/FCF · FCF yield · FCF per share

West Pharmaceutical Services, Inc. (WST) trades at a FCF yield of 2.06% and a price-to-free-cash-flow ratio of 50.0x. FCF per share stands at $6.33, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

2.06%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$6.33

TTM FCF ÷ Shares Outstanding

Price / FCF

x50.0

Share Price ÷ FCF per Share

EV / FCF (TTM)

x48.1

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

WST · cash flow statement · operating / investing / financing

For FY2025, West Pharmaceutical Services, Inc. generated $754.8M in operating cash flow and spent 286M in capital expenditures, yielding $468.9M in free cash flow.

Operating Activities

+$754.8M

Cash from core business operations

2025-12-31

Investing Activities

−$285.9M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$185.1M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($754.8M) − |CapEx| (286M) = FCF ($468.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

WST vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

West Pharmaceutical Services, Inc.YOU

WST

$468.9M+69.6%15.3%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

West Pharmaceutical Services, Inc. (WST) reported free cash flow of $468.9M for FY2025 (fiscal year ending 2025-12-31), up 69.6% year-over-year. The FCF margin was 15.3%.

Based on available data, West Pharmaceutical Services, Inc. has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $468.9M in FY2025. The 5-year CAGR stands at +9.5%.

West Pharmaceutical Services, Inc.'s FCF yield is 2.06% and price-to-FCF ratio is 50.0x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

WST free cash flow · 8 questions

West Pharmaceutical Services, Inc. free cash flow was $468.9M for FY2025, up 69.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $458.0M.

WST free cash flowWST FCFWST FCF 2025WST free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · West Pharmaceutical Services, Inc. · West Pharmaceutical Services, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026